Barnaby Pickering

Barnaby Pickering

Barnaby lives and works in Yorkshire. Having graduated from University College London with a master's degree in biomedical engineering in 2020, Barnaby is passionate about cutting-edge medical technology. Key areas of focus for Barnaby include diabetes, nanotechnology, machine learning and artificial intelligence.

Latest from Barnaby Pickering

Mechanics, Not Microchips: How Simplified Design Could Help Medical Devices Reach More Patients

In an era of AI and other advanced computing methods, pure-play mechanical devices could offer better pricing and practicality, according to the CEO of prosthetics company Metacarpal.

GLP-1 Sales and Fails Could Actually Inflate Gastric Balloon Market

Shantanu Gaur, CEO of Allurion Technologies, a company that has developed a swallowable gastric balloon, believes that GLP-1 sales could indirectly lead to increased demand for medical device-based bariatric procedures, especially as patients seek alternatives to drug side effects and weight regain.

CorWave Ready To Dive Into LVAD Market Following First-In-Human Study

The French start-up has successfully implanted its ‘fishtail’ LVAD in a patient for 84 days, where it served as an effective bridge to transplant. Medtech Insight spoke to the company’s CEO, Louis de Lillers, to hear more about the company’s progress and his take on the evolving LVAD market.

What Exact-ly Is In Store For Liquid Biopsy?

Ahead of Exact Science’s $21bn dollar acquisition by Abbott, Medtech Insight spoke to the company’s chief medical officer, Tomasz Beer, to learn more about the company’s multi-cancer early detection offering, its wider portfolio of products and to hear more about the direction of the field.

Rarity Bioscience Sees Way Forward For superRCA Liquid Biopsy Platform, Despite Challenges

Entering the liquid biopsy market with a new technology remains challenging. Rarity Bioscience CEO Linus Bosaeus, is confident his company’s superRCA could help unlock the true potential of precision medicine as pharma looks more to minimal residual disease as an oncology endpoint.

Prosthetics: Firms Like Unhindr And Esper Shape Market On the Cusp of Great Change

The prosthetics market is evolving due to an increase in amputees from war and disease. Unhindr has developed a novel prostetic liner that can reduce the risk of further injury, while Esper is crafting advanced hand implants for Ukraine's front-line soldiers.